CDKN2B and renal cell carcinoma: Collectively, CDKN2B-AS1/miR-141 is identified as a novel interaction regulating tumorigenic progression and metastasis in RCC through the cyclin-D/Rac/paxillin network, and thus can be an attractive target for therapeutic intervention of aggressive RCC.